Susmita Chennareddy

Susmita Chennareddy

Auto-generated profile, based on publicly available information

Susmita Chennareddy

Department of Otolaryngology Icahn School of Medicine at Mount Sinai New York New York USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2022 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
SMStavros Matsoukas
Stavros Matsoukas
JSJacopo Scaggiante
Jacopo Scaggiante
BSBraxton R. Schuldt
Braxton R. Schuldt
CSColton J. Smith
Colton J. Smith
SCSusmita Chennareddy
Susmita Chennareddy
CKChristopher Kellner
Christopher Kellner

16 June 2022 in BMC Emergency Medicine
Verified
Journal Article
Open access
PDF file
SCSusmita Chennareddy
Susmita Chennareddy
RKRoshini Kalagara
Roshini Kalagara
CSColton Smith
Colton Smith
SMStavros Matsoukas
Stavros Matsoukas
ABAbhiraj Bhimani
Abhiraj Bhimani
CKChristopher P. Kellner
Christopher P. Kellner
Background: The worldwide burden of stroke remains high, with increasing time-to-treatment correlated with worse outcomes. Yet stroke subtype determination, most importantly between stroke/non-stroke and ischemic/hemorrhagic stroke, is not confirmed until hospital CT diagnosis, resulting in suboptimal prehospital triage and delayed treatment. In this study, we survey portable, non-invasive diagnostic technologies that could streamline triage by making this initial determination of stroke type, thereby reducing time-to-treatment. Methods: Following PRISMA guidelines, we performed a scoping review of portable stroke diagnostic devices. The search was executed in PubMed and Scopus, and all studies testing technology for the detection of stroke or intracranial hemorrhage were eligible for inclusion. Extracted data included type of technology, location, feasibility, time to results, and diagnostic accuracy. Results: After a screening of 296 studies, 16 papers were selected for inclusion. Studied devices utilized various types of diagnostic technology, including near-infrared spectroscopy (6), ultrasound (4), electroencephalography (4), microwave technology (1), and volumetric impedance spectroscopy (1). Three devices were tested prior to hospital arrival, 6 were tested in the emergency department, and 7 were tested in unspecified hospital settings. Median measurement time was 3 minutes (IQR: 3 minutes to 5.6 minutes). Several technologies showed high diagnostic accuracy in severe stroke and intracranial hematoma detection. Conclusion: Numerous emerging portable technologies have been reported to detect and stratify stroke to potentially improve prehospital triage. However, the majority of these current technologies are still in development and utilize a variety of accuracy metrics, making inter-technology comparisons difficult. Standardizing evaluation of diagnostic accuracy may be helpful in further optimizing portable stroke detection technology for clinical use.

1 April 2025 in Oral Oncology
Verified
Journal Article
Closed access
SCSusmita Chennareddy
Susmita Chennareddy
SCSida Chen
Sida Chen
CLCarrie Levinson
Carrie Levinson
EGEric M. Genden
Eric M. Genden
MPMarshall R. Posner
Marshall R. Posner
SRScott A. Roof
Scott A. Roof

9 November 2024 in The Laryngoscope
Verified
Journal Article
Closed access
SCSusmita Chennareddy
Susmita Chennareddy
KLKalena H. Liu
Kalena H. Liu
MMMaria A. Mavrommatis
Maria A. Mavrommatis
DKDerek D. Kao
Derek D. Kao
AGAparna Govindan
Aparna Govindan
MCMaura K Cosetti
Maura K Cosetti

8 April 2025 in Neurology
Verified
Journal Article
Closed access
MDMargaret H. Downes
Margaret H. Downes
RKRoshini Kalagara
Roshini Kalagara
CRChristina P. Rossitto
Christina P. Rossitto
VVVikram Vasan
Vikram Vasan
DVDevarshi Vasa
Devarshi Vasa
CKChristopher P. Kellner
Christopher P. Kellner
Cerebral amyloid angiopathy (CAA) is a leading cause of lobar intracerebral hemorrhage (ICH) in older individuals, associated with significant morbidity and recurrence. The updated Boston criteria version 2.0 (v2.0) incorporate new MRI biomarkers to improve diagnostic accuracy. This study aimed to validate the diagnostic performance of v2.0 compared with version 1.5 (v1.5) in patients with spontaneous ICH undergoing surgical evacuation and brain biopsy. This retrospective single-center cohort study was conducted at the Mount Sinai Health System from 2015 to 2021. Patients with spontaneous ICH who underwent surgical evacuation with brain biopsy and preoperative MRI were included. MRI markers assessed included lobar hemorrhagic lesions (ICH, cerebral microbleeds [CMBs], cortical siderosis [cSS]) and nonhemorrhagic markers (severe visible perivascular spaces in the centrum semiovale [CSO-PVS] and multispot white matter hyperintensities [WMHs]). Pathologic confirmation of CAA was based on modified Vonsattel grading, which evaluates β-amyloid deposition in vessel walls. Diagnostic performance of v2.0 was compared with v1.5 using sensitivity, specificity, and predictive values. Logistic regression models calculated odds ratios (ORs) and 95% CIs for associations between MRI biomarkers and pathologically confirmed CAA. Among 186 patients (median age: 63 years; 38% female), 24% had confirmed CAA. The Boston criteria v2.0 demonstrated higher sensitivity for probable CAA (0.75 vs 0.57) while maintaining specificity (0.96 vs 0.99). For possible CAA, sensitivity improved modestly (0.82 vs 0.77) with comparable specificity (0.84 vs 0.87). Among hemorrhagic markers, cSS (OR 4.14, 95% CI 1.35-13.00, p = 0.013) and lobar CMBs (OR 3.03, 95% CI 1.31-7.10, p = 0.009) were significantly associated with CAA. Among nonhemorrhagic markers, CSO-PVS was strongly associated (OR 5.49, 95% CI 2.37-13.06, p < 0.001) while multispot WMHs were not (OR 1.10, 95% CI 0.45-2.56, p = 0.834). The Boston criteria v2.0 enhance sensitivity for diagnosing probable CAA without compromising specificity, largely due to the inclusion of nonhemorrhagic markers such as CSO-PVS. Limitations include the retrospective design, the absence of formal inter-rater reliability measures, and the modest sample size. These findings underscore the potential of v2.0 to improve the diagnostic framework for CAA.

1 September 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
SMStavros Matsoukas
Stavros Matsoukas
SCSusmita Chennareddy
Susmita Chennareddy
RKRoshini Kalagara
Roshini Kalagara
JSJacopo Scaggiante
Jacopo Scaggiante
CSColton J. Smith
Colton J. Smith
CKChristopher Kellner
Christopher Kellner